Morgan Stanley raised the firm’s price target on HCA Healthcare (HCA) to $425 from $400 and keeps an Equal Weight rating on the shares. Q3 results “underscore solid execution,” but “it may be time for a breather” following a strong run up in the stock, the analyst tells investors in a post-earnings note. With the stock up 30% since the Q2 report in late July, the stock could consolidate, though HCA is executing well and remains a bellwether in the group, the analyst added.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $525 from $444 at Cantor Fitzgerald
- HCA Healthcare price target raised to $500 from $400 at Oppenheimer
- HCA Healthcare price target raised to $505 from $475 at Mizuho
- HCA Healthcare: Hold Rating Amid Limited Growth Potential and Policy Uncertainties
- HCA Healthcare price target raised to $475 from $465 at KeyBanc